4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Lihong Chen, Lianxiang Li, Feng Chen, Dalin He. Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma[J]. The Journal of Biomedical Research, 2012, 26(4): 274-277. DOI: 10.7555/JBR.26.20110103
Citation: Lihong Chen, Lianxiang Li, Feng Chen, Dalin He. Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma[J]. The Journal of Biomedical Research, 2012, 26(4): 274-277. DOI: 10.7555/JBR.26.20110103

Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma

More Information
  • Received Date: September 10, 2011
  • We sought to investigate the significance of p53 expression for epithelial ovarian carcinoma. In this study, we used immunohistochemical method to investigate the expression patterns of p53 in different subtypes of epithelial ovarian carcinoma. We found that the expressions of p53 protein in epithelial ovarian cancer (pituita, serosity and intima) were 88.9%, 75% and 100%, respectively, while the recurrence rates among three cancer subtypes were significantly different (33.3%, 12.5% and 0%, respectively; P < 0.05). Compared with patients without lymph node metastasis, the expression of p53 in patients with lymph node metastasis was significantly strong (68.75% and 100%, respectively; P < 0.05). However, the recurrence rate in the patients with lymph node metastasis (40%) was higher than that without lymph node metastasis (6.25%, P < 0.05). The expressions of p53 protein in ovarian cancer between Ⅰ-Ⅱ (25%) stage and Ⅱ-Ⅳ stage (100%) were significantly different (P < 0.05), and the recur-rence rates between the two groups were significantly different (0% and 31.25%, respectively, P < 0.05). There-fore, p53 protein has an intimate relationship with the malignant degree and the prognosis of ovarian cancer.
  • Related Articles

    [1]Ya Xie, Zifeng Xu, Yumin Zhang, Yisheng Li, Pengyu Du, Chun Wang. First-episode psychiatric disorder risk from SARS-CoV-2 infection: A clinical analysis with Chinese psychiatric inpatients[J]. The Journal of Biomedical Research, 2025, 39(1): 50-60. DOI: 10.7555/JBR.38.20240005
    [2]Zheyue Wang, Qi Tang, Bende Liu, Wenqing Zhang, Yufeng Chen, Ningfei Ji, Yan Peng, Xiaohui Yang, Daixun Cui, Weiyu Kong, Xiaojun Tang, Tingting Yang, Mingshun Zhang, Xinxia Chang, Jin Zhu, Mao Huang, Zhenqing Feng. A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling[J]. The Journal of Biomedical Research, 2023, 37(3): 166-178. DOI: 10.7555/JBR.36.20220221
    [3]Jiao Chen, Can Zhao, Yingzi Huang, Hao Wang, Xiang Lu, Wei Zhao, Wei Gao. Malnutrition predicts poor outcomes in diabetic COVID-19 patients in Huangshi, Hubei[J]. The Journal of Biomedical Research, 2022, 36(1): 32-38. DOI: 10.7555/JBR.35.20210083
    [4]Liu Zhi, Wang Jianwei, Ge Yiyue, Xu Yuyu, Guo Mengchen, Mi Kai, Xu Rui, Pei Yang, Zhang Qiankun, Luan Xiaoting, Hu Zhibin, Chi Ying, Liu Xingyin. SARS-CoV-2 encoded microRNAs are involved in the process of virus infection and host immune response[J]. The Journal of Biomedical Research, 2021, 35(3): 216-227. DOI: 10.7555/JBR.35.20200154
    [5]Chen Wei, Hu Zhiliang, Yi Changhua, Chi Yun, Xiong Qingfang, Tan Chee Wah, Yi Yongxiang, Wang Lin-Fa. An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report[J]. The Journal of Biomedical Research, 2020, 34(6): 470-474. DOI: 10.7555/JBR.34.20200099
    [6]Yun Yangfang, Song Hengyi, Ji Yin, Huo Da, Han Feng, Li Fei, Jiang Nan. Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification[J]. The Journal of Biomedical Research, 2020, 34(6): 458-469. DOI: 10.7555/JBR.34.20200044
    [7]Gorzalski Andrew J., Hartley Paul, Laverdure Chris, Kerwin Heather, Tillett Richard, Verma Subhash, Rossetto Cyprian, Morzunov Sergey, Van Hooser Stephanie, Pandori Mark W.. Characteristics of viral specimens collected from asymptomatic and fatal cases of COVID-19[J]. The Journal of Biomedical Research, 2020, 34(6): 431-436. DOI: 10.7555/JBR.34.20200110
    [8]Mehta Neha, Qiao Renli. Medical management of COVID-19 clinic[J]. The Journal of Biomedical Research, 2020, 34(6): 416-421. DOI: 10.7555/JBR.34.20200118
    [9]Slonim Anthony D., See Helen, Slonim Sheila. Challenges confronting rural hospitals accentuated during COVID-19[J]. The Journal of Biomedical Research, 2020, 34(6): 397-409. DOI: 10.7555/JBR.34.20200112
    [10]Yang Wei. Editorial commentary on special issue of COVID-19 pandemic[J]. The Journal of Biomedical Research, 2020, 34(6): 395-396. DOI: 10.7555/JBR.34.20200701
  • Cited by

    Periodical cited type(3)

    1. Ranjbar M, Asadi M, Nourigorji M, et al. Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2. Biotechnol Appl Biochem, 2021. DOI:10.1002/bab.2308. Online ahead of print
    2. Castillo-Olivares J, Wells DA, Ferrari M, et al. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. Front Immunol, 2021, 12: 748291. DOI:10.3389/fimmu.2021.748291
    3. Qasem A, Shaw AM, Elkamel E, et al. Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations. Curr Issues Mol Biol, 2021, 43(2): 728-748. DOI:10.3390/cimb43020053

    Other cited types(0)

Catalog

    Article Metrics

    Article views (3942) PDF downloads (103) Cited by(3)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return